INTRODUCTION
Schizophrenia is a serious mental disorder affecting approximately 1% of the US population [1] and 24 million people worldwide [2] . It is characterized by the occurrence of positive symptoms [3] , such as hallucinations or delusions [4] , and negative symptoms [3] , such as avolition [5] , affective flattening, and social withdrawal [6] .
Though schizophrenia affects a relatively small proportion of the population, it incurs substantial individual, societal, and healthcare costs [7, 8] .
Cognitive deficits are not yet included in the diagnostic criteria for schizophrenia, but are considered a core feature of schizophrenia symptomatology [9, 10] . While neuropsychological impairment may not be present in all patients with schizophrenia [11] , almost all patients with schizophrenia display some cognitive impairment in comparison with healthy controls [12] . Cognitive impairments are often fully developed when patients present with a first episode of illness [13, 14] .
Impairment occurs in most aspects of cognition, including attention, verbal learning and memory, secondary memory, working memory, and executive functions [10, 15, 16] . Indeed, cognitive impairments can reach two standard deviations below the normal mean [10] . These impairments are not the result of positive or negative symptoms, or accounted for by motivational deficits [17] . Furthermore, in most cases, cognitive impairments do not worsen or improve with illness progression [17] .
While cognitive deficits appear to be strong predictors of functional outcome [9] , currently there is no US Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved treatment targeting cognitive impairment associated with schizophrenia (CIAS). Treatments available for schizophrenia include typical and atypical antipsychotics, which predominantly target the positive symptoms of schizophrenia [18] . Despite the availability of antipsychotic medications, patients with schizophrenia are often unsuccessful in re-entering the community [19] and treatments do not appear to improve cognitive function beyond practice effects [20, 21] . Therefore, treatments for cognitive impairment have been identified as an unmet need [22] .
In an effort to improve functional outcomes for patients with schizophrenia, pharmacological research has focused on the improvement of cognitive deficits [23] . Improving patients' treatment experience is also a focus of the US National Institute of Mental Health (NIMH). A primary goal of the MATRICS was to decide on appropriate methods for evaluating new drugs [19] . The MATRICS Consensus Cognitive Battery (MCCB) was designed to provide new conventions for evaluating cognitive deficits in schizophrenia and aid in measuring treatment-related changes [24] . Seven independent cognitive domains were included in the MCCB: speed of processing, attention/ vigilance, working memory, verbal learning and memory, visual learning and memory, reasoning and problem solving (executive functioning), and social cognition [19] . The MCCB consists of 10 cognitive tests designed to assess each domain [24] . C l i n i c i a n -r e p o r t e d o u t c o m e s a n d performance on cognitive tasks are important in assessing patient prognosis and treatment efficacy. However, the patient perspective can also provide valuable insights [25, 26] and may provide a link between cognitive performance and the patient's actual level of real-world functioning [27] . To date, patient-reported outcomes (PRO) instruments have not been evaluated for assessing treatments for CIAS.
To assess PRO instruments and, specifically, 
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Review
Key publications relating to the NIMH MATRICS initiative were also reviewed for information related to impaired cognition in schizophrenia and recommendations for measurement of cognitive function [19, 22, 24, 27, 30, 33] .
Inclusion and Exclusion Criteria
All titles and abstracts were screened for inclusion in the study by two researchers.
To be included, abstracts had to contain a clinical and medication term, a cognition term, and at least one of the PRO or cost terms. Journal articles were limited to English language and human subjects. The selected studies contained keywords in the title or abstract. Studies were excluded only if the reviewers agreed that they did not fulfill the criteria.
Ranking Process
The selected studies were ranked according to whether relevant terms in the title/abstract were: (a) the focus of the article; (b) provided as secondary or exploratory to the focus of the article; or (c) mentioned in the background or the discussion. Only articles ranked 1 were included for further consideration.
Data Extraction
Data extraction tables were developed to extract information accurately on relevant features and results of the selected studies. The key components of the data extraction tables were general information relating to the authors, publication date, country of study, and reference, as well as specific information relating to the aims of the study, patient population, sample size, study design, treatments, cognitive impairment and PRO measurements, main PRO and cognitive impairment results, and key concepts to consider.
Development of Conceptual Model
Key concepts were identified from the published literature, with a particular focus on studies reporting qualitative data from the patient perspective. Relationships between concepts were identified from reported results specifically relating to cognitive impairment.
PRO Instrument Evaluation Criteria
The PRO instruments identified were reviewed according to criteria outlined by the US FDA Guidance for Industry [31] :
• Conceptual framework: Documentation of a diagram that defines concepts measured by the instrument, relationships between items, domain (sub-concepts) and concept measured, and scores produced by a PRO instrument.
• Content validity: Extent to which the instrument measures the concepts of interest (ie, inclusion of items and domains that are appropriate and comprehensive relative to its intended measurement concept, population, and use).
• Psychometric properties: Elements that contribute to the statistical adequacy of an instrument, where relevant, in terms of reliability, construct validity, and ability to detect change.
• Characteristics: Number of items, mode of administration, response options, scoring, and recall period.
Instruments that had been used in ≥3 studies were considered for further review, using FDA PRO guidance. (Fig. 2) . Some cognitive dysfunctions are present during childhood and early adolescence; thus, predating the onset of psychosis [15] . Furthermore, treatment with conventional antipsychotic medication may exacerbate impaired cognitive functioning [34, 35] .
RESULTS
Study Selection
Effects of Treatment on Cognitive
Impairment Associated with Schizophrenia
Although evidence suggests that cognitive deficits are specific to schizophrenia itself and not a side effect of neuroleptic medication [10, 15] , cognitive functions may decline further as a side effect of typical antipsychotics [6, 35] . These appear to have detrimental impact on cognition and functional outcomes [36] . While a lower dosage of some typical antipsychotics may reduce cognitive impairments and some atypical antipsychotic medications do not appear to worsen cognitive impairment, a significant improvement is not apparent. In addition, anticholinergic drugs, used as adjunctive treatment for extrapyramidal side effects, may also affect cognition, particularly memory [37] . Side effects can impact the patient's attitude to medication and may be a cause of nonadherence to the medication regimen [38] .
Humanistic Burden of Cognitive Impairment
Associated with Schizophrenia
Cognitive impairment appears to have a significant impact upon patients' lives; affecting activities of daily living [9] , independent living [6, 18] , social functioning [16, 39, 40] , relationships [41] , and the ability to work [36, 42] ( Fig. 3) . • Impaired attention [6, 35] • Impaired motor processing [6, 35] • Weight gain [43, 44] • Depression [43] • Sedation [43] • Akathisia [35] • Extrapyramidal symptoms [38] • Flattened emotions [35] • Sexual dysfunction [43, 44] Positive symptoms
• Hallucinations [4, 49] • Conceptual disorganization [4] • Unusual thought content [4] • Delusions [4] Negative symptoms
• Avolition [5, 6, 50, 51] • A ective attening [6, 51] • Alogia [6] • Social withdrawal [6, 52] • Anhedonia [52, 51] • Akinesia [52] Activities of daily living
• Washing [56, 60] • Dressing [56, 60] • Cooking [56, 60] • Shopping [18, 60] • Self care [56, 60] • Independent living [18, 60] Relationships [41, 67] • Care-giver [38] • Partner/intimate [41, 56, 67] • Social [41, 67] • Family [41, 67] • Friends [41, 67] Social functioning [16, 34, 43, 61] • Social skills [18] • Social reintegration [38] • Social leisure [39, 40] Occupational functioning [27, 37, 42, 51] • Unemployment [16, 40] • Hours of employment [15] • Number of days worked [65, 66] Cognitive symptoms [35, 38, 43, 45] • Weight gain [35, 38, 43, 45, 46, 47] • Increased cholesterol [45] • Anxiety [48] • Insomnia [48] • Tremor [48] Adjunctive treatments
• Impaired memory [37] • Agitation [37] • Insomnia schizophrenia [7, 8, 69, 70, 74, 78] . Typically, only 20% of patients with schizophrenia find paid employment and 80% are unable to return to work following the first episode of psychosis;
even when paid employment is achieved, job tenure is a frequent problem for patients, who appear to fare worse in the workforce than patients with other mental disorders [78, 79] . From the studies identified, it is not possible to determine which of these costs are directly attributable to cognitive impairment; however, studies have reported a link between cognitive functioning and employment in schizophrenia [42, 79, 80] . Schizophrenia is a costly psychiatric disorder to manage; the annual cost of an average patient with schizophrenia is reported to be significantly higher than other mental health conditions [8] .
This review highlighted a paucity of evidence 
